Last mentioned: Mar 24, 2026
SCOTUS Ruling
Supreme Court dismisses challenge to mifepristone access on standing grounds, preserving status quo.
SCOTUS Ruling
Supreme Court preserves access to mifepristone by ruling plaintiffs lacked standing in FDA challenge.
Retail Pharmacy Entry
Major chains CVS and Walgreens receive certification to dispense abortion pills.
Dobbs Decision
Supreme Court overturns Roe v. Wade, leading to state-level bans.
Dobbs Decision
SCOTUS overturns Roe v. Wade, triggering state-level bans and increasing demand for pills.
Telehealth Expansion
FDA permanently removes in-person dispensing requirements, allowing mail-order access.
Telehealth Shift
FDA permanently removes the requirement that mifepristone be dispensed in person.
Label Update
FDA expands usage to 70 days gestation and reduces required office visits.
Initial FDA Approval
FDA approves Mifepristone for medical termination of early pregnancy.
FDA Approval
FDA approves Mifeprex (mifepristone) for medical termination of pregnancy.
Medication abortion has surged to account for the majority of pregnancy terminations in the U.S., driven by telehealth expansion and mail-order access. This shift has catalyzed a sophisticated legal and legislative counter-offensive aimed at the FDA's regulatory authority and the distribution of pharmaceutical products.
Medication abortion now accounts for the majority of pregnancy terminations in the U.S., driven by telehealth expansion and state shield laws. This shift has triggered a wave of regulatory counter-measures from opponents, focusing on the Comstock Act and FDA approval processes.